ABBISKO-B (02256): IND Application for Combination Therapy of Oral PD-L1 Inhibitor ABSK043 and Shanghai Allist's KRAS G12C Inhibitor for NSCLC Treatment Receives CDE Approval

Stock News

2025/08/20

ABBISKO-B (02256) announced that the IND application for combination therapy using its subsidiary's investigational oral PD-L1 inhibitor ABSK043 and Shanghai Allist Pharmaceuticals Co.,Ltd.'s KRAS G12C inhibitor citrate golaresetib tablets for treating non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations has been approved by China's Center for Drug Evaluation (CDE) under the National Medical Products Administration.

In March 2025, the company's subsidiary reached a collaboration agreement with Shanghai Allist Pharmaceuticals regarding the combination use of ABSK043 and citrate golaresetib tablets. The approved study is "An open-label Phase II clinical trial evaluating the safety, tolerability, and efficacy of ABSK043 combined with citrate golaresetib tablets in patients with locally advanced or metastatic NSCLC harboring KRAS G12C mutations."

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1128157469"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128157469\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128157469?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-20 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128157469","market":"nz","top_or_hot":-1,"title":"ABBISKO-B (02256): IND Application for Combination Therapy of Oral PD-L1 Inhibitor ABSK043 and Shanghai Allist's KRAS G12C Inhibitor for NSCLC Treatment Receives CDE Approval","media":"Stock News","content":"<p>ABBISKO-B (02256) announced that the IND application for combination therapy using its subsidiary's investigational oral PD-L1 inhibitor ABSK043 and Shanghai Allist Pharmaceuticals Co.,Ltd.'s KRAS G12C inhibitor citrate golaresetib tablets for treating non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations has been approved by China's Center for Drug Evaluation (CDE) under the National Medical Products Administration.</p>\n<p>In March 2025, the company's subsidiary reached a collaboration agreement with Shanghai Allist Pharmaceuticals regarding the combination use of ABSK043 and citrate golaresetib tablets. The approved study is \"An open-label Phase II clinical trial evaluating the safety, tolerability, and efficacy of ABSK043 combined with citrate golaresetib tablets in patients with locally advanced or metastatic NSCLC harboring KRAS G12C mutations.\"</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ABBISKO-B (02256): IND Application for Combination Therapy of Oral PD-L1 Inhibitor ABSK043 and Shanghai Allist's KRAS G12C Inhibitor for NSCLC Treatment Receives CDE Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nABBISKO-B (02256): IND Application for Combination Therapy of Oral PD-L1 Inhibitor ABSK043 and Shanghai Allist's KRAS G12C Inhibitor for NSCLC Treatment Receives CDE Approval\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-08-20 19:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>ABBISKO-B (02256) announced that the IND application for combination therapy using its subsidiary's investigational oral PD-L1 inhibitor ABSK043 and Shanghai Allist Pharmaceuticals Co.,Ltd.'s KRAS G12C inhibitor citrate golaresetib tablets for treating non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations has been approved by China's Center for Drug Evaluation (CDE) under the National Medical Products Administration.</p>\n<p>In March 2025, the company's subsidiary reached a collaboration agreement with Shanghai Allist Pharmaceuticals regarding the combination use of ABSK043 and citrate golaresetib tablets. The approved study is \"An open-label Phase II clinical trial evaluating the safety, tolerability, and efficacy of ABSK043 combined with citrate golaresetib tablets in patients with locally advanced or metastatic NSCLC harboring KRAS G12C mutations.\"</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1128157469","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128157469","pubTimestamp":1755689504,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ABBISKO-B (02256) announced that the IND application for combination therapy using its subsidiary's investigational oral PD-L1 inhibitor ABSK043 and Shanghai Allist Pharmaceuticals Co.,Ltd.'s KRAS...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","688578":"艾力斯","BK1515":"抗疫概念","LU1223082519.USD":"SCHRODER ISF GLOBAL GOLD \"A\" (USD) INC AV","CDE":"科尔黛伦矿业","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK1161":"生物科技","BK4023":"应用软件","LU1223082196.USD":"施罗德环球黄金A Acc","BK1574":"生物医药B类股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","PD":"PagerDuty, Inc.","BK4017":"黄金","LU1223083913.SGD":"Schroder ISF Global Gold A Acc SGD-H","09939":"开拓药业-B","02256":"和誉-B","BK0239":"医药制造"},"translate_title":"和必施-B（02256）：口服PD-L1抑制剂ABSK043与上海艾利斯特KRAS G12C抑制剂联合疗法治疗非小细胞肺癌IND申请获CDE批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"688578":1,"09939":1,"CDE":1,"PD":1,"02256":1},"content_text":"ABBISKO-B (02256) announced that the IND application for combination therapy using its subsidiary's investigational oral PD-L1 inhibitor ABSK043 and Shanghai Allist Pharmaceuticals Co.,Ltd.'s KRAS G12C inhibitor citrate golaresetib tablets for treating non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations has been approved by China's Center for Drug Evaluation (CDE) under the National Medical Products Administration.\nIn March 2025, the company's subsidiary reached a collaboration agreement with Shanghai Allist Pharmaceuticals regarding the combination use of ABSK043 and citrate golaresetib tablets. The approved study is \"An open-label Phase II clinical trial evaluating the safety, tolerability, and efficacy of ABSK043 combined with citrate golaresetib tablets in patients with locally advanced or metastatic NSCLC harboring KRAS G12C mutations.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}